Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method
© The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com..
Background: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients.
Methods: Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells.
Results: Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells.
Conclusion: This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Antibody therapeutics - 6(2023), 2 vom: 05. Apr., Seite 76-86 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dou, Yang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 21.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/abt/tbad002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355812819 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355812819 | ||
| 003 | DE-627 | ||
| 005 | 20231226065131.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/abt/tbad002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355812819 | ||
| 035 | |a (NLM)37077472 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dou, Yang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Development of neutralizing antibodies against SARS-CoV-2, using a high-throughput single-B-cell cloning method |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Antibody Therapeutics. All rights reserved. For permissions, please e-mail: journals.permissionsoup.com. | ||
| 520 | |a Background: Rapid and efficient strategies are needed to discover neutralizing antibodies (nAbs) from B cells derived from virus-infected patients | ||
| 520 | |a Methods: Here, we report a high-throughput single-B-cell cloning method for high-throughput isolation of nAbs targeting diverse epitopes on the SARS-CoV-2-RBD (receptor binding domain) from convalescent COVID-19 patients. This method is simple, fast and highly efficient in generating SARS-CoV-2-neutralizing antibodies from COVID-19 patients' B cells | ||
| 520 | |a Results: Using this method, we have developed multiple nAbs against distinct SARS-CoV-2-RBD epitopes. CryoEM and crystallography revealed precisely how they bind RBD. In live virus assay, these nAbs are effective in blocking viral entry to the host cells | ||
| 520 | |a Conclusion: This simple and efficient method may be useful in developing human therapeutic antibodies for other diseases and next pandemic | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Xu, Ke |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Yong-Qiang |e verfasserin |4 aut | |
| 700 | 1 | |a Jia, Zijing |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Xiaoyu |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Guorui |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Tianshu |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xiangxi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Xinquan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Lingjie |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Pan |e verfasserin |4 aut | |
| 700 | 1 | |a Qin, Cheng-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Hong |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yafeng |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Guizhen |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kang |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Bai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Antibody therapeutics |d 2018 |g 6(2023), 2 vom: 05. Apr., Seite 76-86 |w (DE-627)NLM287402134 |x 2516-4236 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:2 |g day:05 |g month:04 |g pages:76-86 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/abt/tbad002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 2 |b 05 |c 04 |h 76-86 | ||